Remember meForgot password?
    Log in with Twitter
Press Release

Zofran Lawsuit Plaintiffs Note Results Of Japanese Animal Studies Linking Birth Defects To Drug reports on the concerning results of Japanese animal studies which appear to lend support to the allegations of plaintiffs currently involved in Zofran birth defect lawsuits by linking exposure to the drug by animal fetuses to an increased risk of birth defect development. Just months after over 200 parents have stepped forward filing Zofran birth defect related lawsuits, the complaints have been transferred and consolidated to a single federal court in Boston. On December 11, 2015, Zofran manufacturer and defendant GlaxoSmithKline requested that these cases be dismissed.

This motion was later dismissed by overseeing Judge F. Dennis Saylor IV, but it has been reported that it will be able to be requested again in the future. Plaintiffs responded to GSK’s request for dismissal, by noting that there was, “reason to believe that GSK had important evidence about the defects alleged [...], and the link to Zofran.” To better illustrate this point, plaintiffs pulled in concerning information from the results from several “animal teratogenicity studies” which GSK had arranged be conducted in Japan. The study results seem to link animal fetal Zofran exposure to the development of congenital heart defects, an allegation that many plaintiffs who used the drug while pregnant say has happened to their own children.

Plaintiffs claim that the Japanese studies highlighted pregnant animals who were exposed to Zofran and who subsequently gave birth to offspring with ventricular septal defects of the heart. They additionally indicate that these important studies took place after the drug had been given FDA approval for U.S. sales. A common point of contention, however, is that Zofran was never FDA-approved to treat expectant mothers or tested for safety on this consumer group. Despite this fact, however, manufacturer GSK reportedly went on to market the drug as a safe and effective treatment for nausea associated with morning sickness.

If the concerning test result allegations are proven to be true, pharmaceutical giant GSK could face increasing public scrutiny for potentially concealing their product’s possible connection to the development of fetal birth defects. Plaintiffs anxiously await their day in trial as litigation moves forward. During this time, the attorneys of Monheit Law are working to help other mothers who have used the drug while pregnant and who have gone on to give birth to children with defects. Affected mothers, children, and families could be entitled to significant compensation attained through legal action, and are encouraged to take the important opportunity to fully explore their legal rights in the matter. To better assist those wanting to further investigate their options, the attorneys of Monheit Law are currently offering free legal consultations for qualified parties.

To request further information on Zofran birth defect lawsuits, or to ask questions, please contact Michael Monheit, Esq. by calling 877-620-8411.



Michael Monheit
1368 Barrowdale Road, Rydal, PA 19046

Latest News
Top News